BLAINTRATRACHEALSUSPENSION
Approved
Jul 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SURVANTA (beractant) by AbbVie is surfactant activity [moa]. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURVANTA (beractant) is a natural lung surfactant suspension administered intratracheally to treat respiratory distress syndrome in premature infants. It works by restoring surfactant activity in the lungs, reducing surface tension and improving gas exchange. This is a foundational neonatal critical care therapy approved over 30 years ago.
LOE Approaching
As LOE approaches, the brand faces moderate generic competition (30% pressure score), suggesting opportunities in defensive strategies and niche market positioning rather than growth expansion.
Mechanism of Action
Surfactant Activity
Pharmacologic Class:
Surfactant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SURVANTA offers stability in a mission-critical neonatal therapy but limited growth trajectory. Career advancement will emphasize defensive market strategy, hospital relationships, and cost-containment rather than launch excitement or indication expansion.
Brand ManagerAccount Executive (Hospital/Neonatal)
Worked on SURVANTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.